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Abstract
Purpose: We perform a clinical retrospective study to determine whether a vaginal balloon-packing system provides
a dosimetric reduction to organs at risk (OARs) versus traditional gauze packing for gynecological high-dose-rate 
brachytherapy (HDR-BT). We also test various balloon filling materials for optimizing imaging quality. 
Material and methods: Filling materials for balloon-packing were evaluated based on imaging quality with X-ray,
computerized tomography, and magnetic resonance imaging modalities. We then retrospectively reviewed 45 HDR-BT
plans of 18 patients performed with gauze packing and 39 plans of 16 patients performed with balloon-packing. Twelve
patients received both gauze and balloon-packing. HDR-BT was delivered with an iridium-192 afterloader and a Fletch-
er-Suit-Declos-style T&O applicator. At each fraction, 3D imaging was obtained. The D2cc values of OARs were calcu-
lated, as well as ICRU-defined point doses. 
Results: In the 84 HDR fractions reviewed, vaginal balloon-packing provides statistically equivalent doses to rec-
tum, bladder, and sigmoid compared to gauze packing. On average balloon-packing produced average reductions of
3.3% and 6.9% in the rectal and sigmoid D2cc doses and an increase of 3.2% to the bladder D2cc dose (normalized to pre-
scription dose), although none of these values were statistically significant for the twelve patients who received both
gauze and balloon-packing (32 and 40 total fractions, respectively). 
Conclusions: In the 84 HDR fractions analyzed, vaginal balloon-packing is as effective as gauze packing for dose
sparing to the rectum, bladder, and sigmoid. A 1 : 1 solution of saline and contrast for filling material enables easy con-
touring for image-guided HDR with minimal artefacts.
J Contemp Brachytherapy 2013; 5, 1: 17–22 
DOI: 10.5114/jcb.2013.34449






Brachytherapy (BT) plays an essential role in the treatment
of both endometrial cancer and carcinoma of the cervix [1,2].
The use of high-dose-rate (HDR) BT, typically with an irid-
ium-192 remote afterloader, has become increasingly com-
mon for reasons of patient convenience, comfort, and expense
[3,4]. The most commonly used HDR intracavitary appli-
cators are the tandem-and-ovoids applicator (T&O), and the
tandem-and-ring applicator. The prescription dose calcu-
lation and dose calculation to the organs at risk (OAR) rec-
tum and bladder are historically performed using the
point-based Manchester system on orthogonal radiographs
[3,5], in which the radiation dose is prescribed to point A,
located 2 cm superiorly along the tandem from the lateral
vaginal fornix and 2 cm laterally to the tandem [6,7]. 
Traditionally, vaginal gauze packing has been used af-
ter applicator placement. This packing serves two impor-
tant functions: immobilizing the applicator and increasing
the distance between the radioactive source and the OARs,
which subsequently decreases the OAR dose. Toxicities from
gynecological BT manifest with a spectrum of clinical side-
effects ranging from urinary urgency rectal pain and rec-
tal bleeding to chronic ulceration and vaginal fistulas. As
an alternative to gauze packing, a commercial vaginal bal-
loon-packing system was introduced that consists of two
balloons which fit anteriorly and posteriorly over the BT ap-
plicator. There are several potential benefits to this system
over traditional gauze-packing, including increased re-
producibility among fractions, increased patient comfort,
and a decreased risk of vaginal laceration during packing. 
Three-dimensional (3-D) image-guided HDR-BT uses
computed tomography (CT) or magnetic resonance imag-
ing (MRI) to allow clinicians to verify proper placement of
an applicator, and to allow for customized treatment plans
to deliver dose to the tumor and spare OARs. The use of MRI
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in HDR-BT is currently gaining momentum [8,9] due to its
high soft tissue contrast, which provides better definition
of the macroscopic tumor. Commonly referenced volumetric
dose parameters include the D2cc, which is the dose in the
“hottest” 2cc of a structure, as opposed to the traditional rec-
tal and bladder point doses defined on 2-D imaging by the
International Commission on Radiation Units and Measu -
rements (ICRU) report #38 [5]. 
While a previously published study used Monte Carlo
modelling to show a theoretical 6-15% dose reduction to
OARs using vaginal balloon-packing [10] due to the atte -
nuating effect of a high CT-number contrast material used
as filling, to our knowledge, no clinical studies concerning
the dosimetry of vaginal balloon-packing have been re-
ported. In this study, we investigate whether balloon-pack-
ing provides superior dose reduction to OARs compared
with traditional gauze packing. We hypothesize that the in-
creased reproducibility afforded by the balloon-packing sys-
tem and improved treatment geometry would on average
lead to decreased OAR doses compared to gauze packing,
due to the inherent variability in quality of gauze packing.
Toward this end, we describe a retrospective volume-based
dosimetric analysis of OAR doses from HDR-BT plans per-
formed with either gauze or balloon-packing. Additional-
ly, dosimetric comparisons are made among fractions for
patients who received both gauze and balloon-packing dur-
ing the course of their treatment. 
Material and methods
Patients and treatment: EBRT and HDR
Twenty-two patients with biopsy-confirmed cervical 
cancer who received HDR-BT were selected for this study.
The use of patient data was approved by our Institutional
Review Board. The patients’ International Federation of 
Gynecology and Obstetrics (FIGO) stages ranged from IB2
to IIIB. Institutional standard-of-care treatment consisted
of external beam radiation therapy (EBRT) with weekly
chemotherapy (typically platinum based) integrated with
HDR-BT. EBRT was 45 Gy in 25 fractions to the whole pelvis.
Patients with parametrial involvement received an EBRT
boost of 5.4 Gy in 3 fractions to the parametrium. After 
3-4 weeks of EBRT, HDR-BT using a VariSource iX® remote
afterloading unit (Varian Medical Systems Inc., Palo Alto,
California, USA) was started with a nominal 7 day interval
between fractions. A titanium Fletcher-Suit-Delclos style
T&O® (Varian Medical Systems Inc.) was used for all cas-
es. The T&O was inserted under general anesthesia after
a clinical examination. Ultrasound guidance was perform -
ed for each T&O insertion. 
After the applicator was inserted, a high-resolution 
(3.0 Tesla) MRI scan was acquired with aMAGNETOM Trio
3T MR® scanner (Siemens Medical Solutions Inc., Erlangen,
Germany) with the use of both spine and body array coils.
Detailed 3.0 Tesla MRI scan parameters can be found in
a previously published study [11]. Other studies have ex-
amined the issues surrounding the use of titanium appli-
cators in a high-resolution (3.0 Tesla) MRI scanner includ-
ing safety, artefacts, and distortions [11,12]. Three HDR
fractions in this study (3 out of 84) were planned using CT
due to the unavailability of the MR scanner on the treatment
day. Orthogonal digital radiographs, using a C-arm fluo-
roscopy unit (ACARDIS Orbit®, Siemens Medical Solutions
Inc.) were acquired in the HDR treatment room before and
after the 3-D imaging scan (CT or MRI) to confirm that the
applicators had not moved during patient transfer. 
Our institutional standard HDR prescription scheme is
5.5 Gy times 5 fractions or 7 Gy times 4 fractions with 7 day
intervals, integrated with EBRT so that the radiation
course is finished within 7 weeks [3]. HDR treatment plans
were performed based upon the conventional Manchester-
based system [3,13], in which radiation dose is prescribed
to point A. The BrachyVision version 8.9® (Varian Medical
Systems Inc.) treatment planning system was used for HDR
planning and dose volume histogram analysis. 
Vaginal packing procedure
After the T&O applicator was positioned, either gauze
or balloon-packing (the Alatus® Vaginal Balloon Packing
System, Radiadyne LLC., Houston, Texas, USA) was used
to immobilize the applicator. For gauze-packing, a roll of
gauze was soaked in sterile normal saline. Beginning at the
proximal vagina, approximately 5 cm segments of gauze
were inserted with forceps, alternating anteriorly and
posteriorly to the applicator. Gauze insertion continued un-
til the vaginal introitus was reached and the applicator re-
mained snugly in place. 
The balloon-packing system consists of two balloons
which are inserted anteriorly and posteriorly to the appli-
cator. A 50 cc syringe was filled with a solution of one part
normal saline and one part ISOVUE-250® contrast (Bracco
Diagnostics Inc., Princeton, New Jersey, USA). This syringe
was used to alternately fill the anterior and posterior bal-
loons in 10 cc increments. Each balloon was typically filled
with 30 cc to 50 cc of solution depending on the vaginal size. 
Commissioning vaginal balloon-packing
Various balloon filling materials were examined, includ -
ing air, water, 100% contrast, 100% normal saline, and 
a 1 : 1 solution of normal saline and contrast (Fig. 1). The op-
 timal filling material was determined using two metrics:
favourable imaging qualities on orthogonal radiograph, CT,
and MRI modalities (most importantly lack of artefact), and
also radiation attenuation capacity. A quality assurance 
(QA) phantom, previously developed to perform QA for CT
or MRI-guided HDR [11], was also used in this study. 
The Hounsfield Unit (HU) values on CT were quantified to
estimate the radiation attenuation potential for the various
filling materials. The vaginal balloon-packing material
which best balanced imaging characteristics with the po-
tential for dose attenuation was clinically implemented. 
Dosimetric evaluation
To perform in vivo dosimetric evaluations, we retro-
spectively reviewed 45 HDR plans of 18 patients that were
performed with gauze packing and 39 plans of 16 patients
performed with balloon-packing. Twelve patients received
both gauze and balloon-packing. The rectum, bladder, and
sigmoid were contoured on high-resolution (3.0 Tesla) MRI
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or CT scans, according to the GEC-ESTRO-EMBRACE
guidelines [8]. Values for D2cc of the OARs were used as
metrics to compare the dosimetric impact of vaginal pack-
ing, along with conventional ICRU report #38-defined 
rectal and bladder point doses. Both the ICRU point dos-
es and the D2cc values were converted to a percentage-
of-prescription dose for that fraction by dividing by the 
prescription dose and multiplying by 100 (referred to as
%ICRU or %D2cc). This was done to normalize to the pre-
scription dose (5.5 Gy or 7 Gy). The average ICRU, %ICRU,
D2cc, and %D2cc values for the OARs were calculated for
gauze and balloon-packing, as well as standard deviations.
The p-values were calculated using Microsoft Excel using
a two-tailed t-test assuming homoscedasticity. 
An “intra-patient” comparison of balloon and gauze
packing was conducted for twelve patients who received both
gauze and balloon-packing at different fractions during the
course of their treatments. These patients each received 1-3
fractions packed with gauze and 1-4 fractions packed with 
balloons. The %ICRU and %D2cc doses were calculated as 
described above for the ICRU point doses and the image-based
D2cc values, respectively. For those patients who received more
than one fraction with a particular packing type, values were
averaged and the standard deviation was calculated. 
Results
Balloon filling material
We found that air filling was suboptimal for balloon-
packing due to the loss of attenuation potential. Saline pro-
vided both a degree of attenuation (62 ± 32 HU) and satis-
factory image quality on radiographs and CT, showing the
vaginal wall clearly with no artefacts, and on T2-weighted
MRI with high MR signal. Contrast used as filling produced
a high HU (2790 ± 585), which was potentially promising
for further attenuation to the OARs, but imaging artefacts
were unacceptable (Fig. 1). A 1 : 1 mixture of saline and con-
trast produced acceptable imaging on orthogonal radio -
graphs, CT, and MRI with a HU value of 1882 ± 449, also
promising for potential attenuation. The 1 : 1 saline and 
contrast filling was selected for our institutional protocol
for MRI-guided BT. Both radiographs and MRI (T1 & T2-
weighted) with balloon-packing showed the vaginal wall
clearly, aiding with contouring during treatment planning.
Dosimetric analysis
A summary of the dosimetric comparison between bal-
loon-packing and gauze packing is shown in Table 1. Bal-
loon-packing provided a non-statistically significant reduc -
tion in the D2cc rectal dose expressed as a percentage of the
prescription (53.1% balloon vs. 60.7% gauze, p = 0.07). Like-
wise, the bladder and sigmoid D2cc volumetric doses and
the ICRU rectal and bladder point doses were statistically
equivalent between balloon-packing and gauze packing. The
bladder D2cc dose was higher for balloon packing (98.1%
balloon vs. 87.7% gauze, p = 0.16), but again, this was not
statistically significant. 
In order to account for anatomic differences, a compari -
son of OAR doses was made among fractions within the
same patients, i.e., 12 patients who received both gauze and
balloon-packing alternatively at different fractions during
the courses of their treatments (Table 2). Each patient re-
ceived 1-4 fractions of both packing types. For these twelve
patients as a group, balloon-packing produced average re-
ductions of –3.3%, and –6.9% in the rectal and sigmoid D2cc
doses, and an increase of +3.2% in the bladder D2cc dose (ex-
pressed as a percentage of the prescription dose). There were
–3.5% and –4.8% reductions in the rectal and bladder ICRU
point doses as a percentage of the prescription doses. None
of these values were statistically significant. 
Discussion
Gauze has been utilized as vaginal packing for gyne-
cological BT for decades with traditional 2-D orthogonal im-
aging. The quality of gauze packing is highly dependent on
the experience and skill of the oncologist performing the pro-
cedure. Potential pitfalls include not packing tightly
enough or an uneven distribution of gauze between the 
anterior and posterior parts of the applicator. At our insti -
tution, the applicator is placed while the patient is under
general anaesthesia, but aggressive packing can be very un-
comfortable for sedated patients. The vaginal wall is also
susceptible to laceration during the packing process, caus-
ing further potential morbidity to the patient and increas-
ing the total procedure time if sutures are required.
Balloon-packing addresses many of the problems with
gauze packing. We hypothesized that balloon-packing would
decrease dose to the OARs by increasing distance from
sources and a more favourable geometry. Saini et al. [10] 
reported contrast-filled balloons showed 7.8% and 19.2%
dose reductions through diode measurement when com-
pared to saline- and air-filled balloons, respectively. Monte
Carlo modelling also predicted 10.5% and 21.9% dose re-
ductions in contrast-filled balloons, compared to saline- and
air-filled balloons, respectively. In this study, ISOVUE-250
contrast was used in which iodine is the effective element
and has 33 keV K-shell electron binding energy. Thus, io-
dine has a high attenuation coefficient due to the photo-
electric effect for low energy X-rays or gamma-rays. En-
hanced photon absorption in the solution is, therefore,
expected to be due to the large number of the photoelectric
events, because of the presence of iodine. No study has been
reported, validating dose reduction on OAR due to the use
of contrast-filled balloon packing using clinical datasets. This
is an area for future research. 
In our analysis of 84 HDR fractions, we did not find that
balloon packing made a statistically significant difference
in the bladder, rectal, or sigmoid OAR doses using either
ICRU point criteria or a volumetric D2cc analysis. Anatom-
ical variation in these OARs may explain why there was not
a significant reduction in doses to these structures with bal-
loon-packing compared to gauze packing. This variation is
seen among patients and also among fractions for the same
patient. In an attempt to account for the former, we com-
pared both packing types in twelve patients who received
gauze and balloon-packing during the courses of their treat-
ments. In this analysis, balloon-packing did produce a slight
average reduction in dose for the rectum and sigmoid (3.3%
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and 6.9%), but an equally slight increase in dose to the blad-
der (3.2%). These values were not statistically significant.
Among these twelve patients, many patients often had
suboptimal high bladder doses for at least one fraction, re-
gardless of the packing type (Table 2). Notably, the ICRU
bladder point dose was often deceptively within normal lim-
its (< 80% of the prescribed dose), but the image-based D2cc
was over 100% of the prescribed dose. The disconnection be-
tween ICRU point doses and image-based dosimetry has
been previously noted [14], and image-based dosimetry has
been shown to be more clinically relevant in terms of side
effects [15]. Our current study further underscores the im-
portance of volume-based dosimetry in brachytherapy
planning. 
In a patient with a very anteverted uterus, portions of the
bladder may be unavoidably near the tandem and there-
fore in the high-dose radiation isodose levels regardless of
the type of packing used. Similarly, the anatomic location
of the sigmoid colon varies among patients and among frac-
tions, and its location with respect to the radiation isodose
distribution is often unaffected by the type or degree of pack-
ing, since it is physically distant from the vagina.
When we started using balloon-packing in our practice,




Gauze Balloon ∆ p Gauze Balloon ∆ p Gauze Balloon ∆ p
6.1 ± 0.7 Gy 6.2 ± 0.7 Gy 0.52 6.1 ± 0.7 Gy 6.2 ± 0.7 Gy 0.52 6.1 ± 0.7 Gy 6.2 ± 0.7 Gy 0.52
ICRU 3.7 ± 1.3 Gy 3.3 ± 1.2 Gy –0.4 Gy 0.14 4.4 ± 1.9 Gy 4.3 ± 2.2 Gy –0.1 Gy 0.78
%ICRU 60.7 ± 19% 53.1 ± 18.4% –7.6% 0.07 71.5 ± 26.1% 69.5 ± 37.4% –2.0% 0.78
D2cc 3.8 ± 1.1 Gy 3.5 ± 1.2 Gy –0.3 Gy 0.21 5.4 ± 1.6 Gy 6.1 ± 2.6 Gy +0.7 Gy 0.14 3.7 ± 1 Gy 3.5 ± 1.4 Gy –0.2 Gy 0.31
%D2cc 62.4 ± 14.2% 56.5 ± 17% –5.9% 0.09 87.7 ± 21.1% 98.1 ± 43.8% +10.4% 0.16 61.6 ± 14.6% 55.9 ± 20.4% –5.7% 0.15
Table 1. Retrospective dosimetric analysis of 45 HDR brachytherapy plans performed with gauze packing and
39 plans performed with vaginal balloon packing. Mean values and standard deviations are shown below, as
well as p-values from a two-tailed t-test. The average dose per fraction was similar between the gauze packing
and balloon packing groups (6.1 Gy and 6.2 Gy). ICRU rectal and bladder point doses and the D2cc values for
the rectum, bladder, and sigmoid were calculated. %ICRU and %D2cc refer to the ICRU and D2cc values as a per-
centage of the prescription doses 
Prescription – prescriptions for all 45 HDR plans, Gauze – gauze packing data, Balloon – vagina balloon packing data, ∆ – the mean difference of balloon–gauze (neg-
ative represents dose reduction at balloon), p – p values, ICRU – ICRU report #38 defined rectal and bladder point doses, %ICRU and %D2cc – ICRU and D2cc values
as a percentage of the prescription doses
Difference in rectum Difference in bladder Difference in sigmoid
ICRU %ICRU D2cc %D2cc ICRU %ICRU D2cc %D2cc D2cc %D2cc
[Gy] [%] [Gy] [%] [Gy] [%] [Gy] [%] [Gy] [%]
Patient 1 –1.1 –15.2 –3.0 –43.1 –1.6 –22.7 –4.9 –69.4 –0.9 –12.9
Patient 2 +0.7 +12.7 +0.3 +4.9 –1.4 –24.9 +0.9 +16.8 –0.2 –3.5
Patient 3 –0.2 –3.1 +1.0 +14.9 –0.4 –5.4 +3.1 +44.0 +0.7 +9.6
Patient 4 –3.1 –43.8 –2.2 –30.9 –0.9 –12.8 –0.7 –10.1 –1.5 –20.7
Patient 5 –1.3 –23.5 –0.7 –12.7 –0.8 –13.8 –1.0 –17.8 –0.5 –8.3
Patient 6 +0.2 +6.6 –0.9 –9.4 +2.8 +48.0 +1.7 +31.1 –1.2 –14.4
Patient 7 +1.5 +20.7 +2.0 +28.1 –2.8 –40.1 –2.6 –37.5 +0.2 +2.6
Patient 8 +0.5 +7.1 +0.7 +10.4 +0.8 +11.3 +1.5 +21.7 +0.6 +7.8
Patient 9 –0.1 –1.0 –0.2 –3.1 –0.3 –4.7 +0.2 +2.5 –0.6 –7.9
Patient 10 +0.3 +4.0 0.0 +0.6 +2.4 +34.3 +2.1 +30.1 –1.5 –20.6
Patient 11 –0.9 –16.0 +0.3 +6.0 –0.3 –5.9 +0.9 +16.4 +0.6 +10.1
Patient 12 +0.5 +9.4 –0.3 –5.1 –1.2 –21.2 +0.6 +10.9 –1.4 –24.8
Average –0.2 –3.5 –0.2 –3.3 –0.3 –4.8 +0.1 +3.2 –0.5 –6.9
Std dev 1.2 19.1 1.5 21.2 1.8 27.2 2.4 35.3 0.8 10.9
P value 0.52 0.48 0.58 0.55 0.75 0.70 0.85 0.74 0.26 0.31
Table 2. The dosimetric differences of 12 intra-patients who received both gauze and balloon packing. Negative
represents dose reduction in balloon packing 
Difference – the difference of balloon packing data – gauze packing data, ICRU – ICRU report #38 defined rectal and bladder point doses, %ICRU and %D2cc – ICRU
and D2cc values as a percentage of the prescription doses
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minal 40 cc as recommended by the vendor. Most patients
in this study were treated according to these instructions.
In contrast, when using gauze packing, the volume of pack-
ing is not set for each fraction, and the amount of packing
a patient receives may vary from fraction to fraction based
on the physician’s skill and judgment. Nevertheless, we
demonstrate that even with vendor recommended filling,
we achieve, on average, comparable, if not better, dose spar-
ing to OARs with balloon-packing. We believe that this
demonstrates the major benefit of balloon-packing, which
is a consistent quality of packing from fraction to fraction
that minimizes the reliance on technique. We have recent-
ly begun to increase the filling volume of each balloon to
50 cc if allowed by the patient’s anatomy, which could con-
ceivably provide some additional degree of dosimetric spar-
ing to the OARs.
We show in this study that while there is not a dosimetric
advantage to using balloon packing, an extensive analysis
of 84 HDR fractions shows balloon packing provides sta-
tistically equivalent dosimetric protection to the OARs. This
should provide reassurance to clinicians using balloon pack-
ing for reasons of patient comfort and convenience and may
also suggest balloon packing as an appropriate selection for
low-volume HDR centers with less experience with gauze
packing. There are not enough patients and there has not
been sufficient follow-up to know whether there are any dif-
ferences in clinical outcomes between the two groups of pa-
tients. In the short term, we have not noted any significant
differences in the acute side effect profiles.
Conclusions
To our knowledge, this is the first clinical analysis of the
dosimetric performance of a commercially available vagi-
nal balloon-packing system. We show that based on volu-
metric dosimetry, balloon-packing provides a statistically
equivalent OAR protection in the 84 HDR fractions analyz -
ed. Balloon-packing provides significant clinical benefits,
including patient comfort and safety and time savings. Al-
though we did not show that balloon packing is able to sig-
nificantly lower OAR doses through geometry optimization,
clinical demonstration of a possible dose reduction sec-
ondary to attenuation by a high-Z balloon filling material
does remain an area for future research.
Despite the promise of using image-guided HDR to de-
liver more personalized, conformal radiation to patient’s
actual tumor volumes as opposed to the historical Man-
chester points, HDR delivery is ultimately constrained by
the physical geometry of the implant, which in turn is dic-
tated by the patient’s anatomy and OAR constraints. New
paradigms, including balloon-packing, offer additional
tools for increasing the therapeutic ratio of brachythera-
py, either by optimizing the geometry of the implant, or
possibly through physical means such as introducing some
degree of radiation attenuation in the balloon filling ma-
terial.
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